影像学技术在霍奇金淋巴瘤诊疗中的价值

戴娜; 吴翼伟; 戴娜; 吴翼伟

doi:10.3760/cma.j.issn.1673-4114.2014.02.011

[1]

Roman E, Smith AG. Epidemiology of lymphomas[J]. Histopathology, 2011, 58(1): 4-14.

[2]

白人驹, 张雪林.医学影像诊断学[M]. 3版.北京:人民卫生出版社, 2010: 6-10.

[3]

Cabanillas F, Fuller LM. The radiologic assessment of the lymphoma patient from the standpoint of the clinician[J]. Radiol Clin North Am, 1990, 28(4): 683-695.

[4]

Enhert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial[J]. J Clin Oncol, 2007, 25(23): 3495-3502. doi: 10.1200/JCO.2006.07.0482

[5]

Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatmentof patients with advanced Hodgkin′s lymphoma: results from the HD2000 Group Italiano per lo Studio dei Linfomi Trial[J]. J Clin Oncol, 2009, 27(5): 805-811. doi: 10.1200/JCO.2008.17.0910

[6]

Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin′s lymphoma[J]. N Engl J Med, 2010, 363(7): 640-652. doi: 10.1056/NEJMoa1000067

[7]

李琼, 白人驹, 孙浩然, 等. MR DWI在淋巴瘤检出、疗效监测中的应用[J].中国医学影像技术, 2010, 26(12): 2313-2316.

[8]

Mürtz P, Krautmacher C, Träber F, et al. Diffusion- weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 tesla[J]. Eur Radiol, 2007, 17(12): 3031-3037. doi: 10.1007/s00330-007-0717-8

[9]

Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging[J]. J Nucl Med, 2004, 45(9): 1509-1518.

[10]

Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro -2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience[J]. Ann Nucl Med, 2007, 21(4): 209-215. doi: 10.1007/s12149-007-0010-6

[11]

Punwani S, Taylor SA, Bainbridge A, et al. Pediatric and adolescent lymphoma: comparison of whole-Body STIR Half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging[J]. Radiology, 2010, 255(1): 182-190. doi: 10.1148/radiol.09091105

[12]

Okada M, Sato N, Ishii K, et al. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma[J]. Radiographics, 2010, 30(4): 939-957. doi: 10.1148/rg.304095150

[13]

Rahmouni A, Luciani A, Itti E. MRI and PET in monitoring response in lymphoma[J/OL]. Cancer Imaging, 2005, 5: 106-112[2013-05-19]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665309.

[14]

Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging[J]. AJNR Am J Neuroradiol, 2008, 29(3): 471-475. doi: 10.3174/ajnr.A0872

[15]

Chun CW, Jee WH, Park HJ, et al. MRI features of skeletal muscle lymphoma[J]. AJR Am J Roentgenol, 2010, 195(6): 1355-1360. doi: 10.2214/AJR.09.3904

[16]

Politi LS, Forghani R, Godi C, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring[J]. Radiology, 2010, 256(2): 565-574.

[17]

胡兴荣, 冉瑞智, 张家权, 等.全身扩散加权成像在恶性淋巴瘤诊断中的价值[J].放射学实践, 2010, 25(8): 892-895.

[18]

Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma[J]. Cancer, 2002, 94(4): 879-888. doi: 10.1002/cncr.10336

[19]

Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison[J]. Leuk Lymphoma, 2004, 45(1): 85-92.

[20]

Connors JM. Positron emission tomography in the management of hodgkin lymphoma[J/OL]. Am Soc Hematol Educ Program, 2011, 2011: 317-322[2013-05-19]. http://www.ncbi.nlm.nih.gov/pubmed/22160052.

[21]

Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol, 2007, 25(5): 571-578. doi: 10.1200/JCO.2006.08.2305

[22]

Picardi M, Soricelli A, Grimaldi F, et al. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin′s lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen[J]. Ann Oncol, 2011, 22(3): 671-680. doi: 10.1093/annonc/mdq403

[23]

马林峰, 樊卫.淋巴瘤病灶对¹⁸F-FDG摄取与不同病理亚型的关系[J].癌症, 2009, 28(4): 425-430.

[24]

Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in Hodgkin′s disease and aggressive non-Hodgkin′s lymphoma and its impact on clinical management[J]. Q J Nucl Med Mol Imaging, 2008, 52(1): 9-16.

[25]

吴维颢, 程志祥, 王伟光, 等. 56例霍奇金淋巴瘤的回顾性分析[J].临床血液学杂志, 2012, 25(3): 140-143.

[26]

Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma[J]. J Nucl Med, 2009, 50 Suppl 1: 21S-30.

[27]

Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine(CALGB 50203) for stage Ⅰ/Ⅱ nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET[J]. Blood, 2011, 117(20): 5314-5320. doi: 10.1182/blood-2010-10-314260

[28]

Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin′s lymphoma[J]. Ann Oncol, 2011, 22(4): 910-915. doi: 10.1093/annonc/mdq549

[29]

Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin′s lymphoma[J]. Ann Oncol, 2010, 21(1): 126-132. doi: 10.1093/annonc/mdp271

[30]

Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin′s lymphoma has a high negative predictive value[J]. Ann Oncol, 2009, 20(7): 1270-1274. doi: 10.1093/annonc/mdn768

[31]

Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin′s lymphoma: a report from a joint italian-danish study[J]. J Clin Oncol, 2007, 25(24): 3746-3752. doi: 10.1200/JCO.2007.11.6525

[32]

Barnes JA, LaCasce AS, Zukotynski K, et al. End of treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin′s lymphoma[J]. Ann Oncol, 2011, 22(4): 910-915. doi: 10.1093/annonc/mdq549

[33]

Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin′s lymphomas. NCI Sponsored International Working Group[J]. J Clin Oncol, 1999, 17(4): 1244. doi: 10.1200/JCO.1999.17.4.1244

[34]

Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-586. doi: 10.1200/JCO.2006.09.2403

[35]

Re A, Ferrari S, Frata P, et al. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin′s lymphoma. A prospective phase Ⅱ study[J]. Ann Oncol, 2008, 19(5): 951-957. doi: 10.1093/annonc/mdm596

[36]

Mocikova H, Obrtlikova P, Vackova B, et al. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study[J]. Ann Oncol, 2010, 21(6): 1222-1227. doi: 10.1093/annonc/mdp522

[37]

龚红霞, 路青, 朱炯, 等. 3.0T磁共振弥散加权成像和表观弥散系数在淋巴瘤诊断中的价值[J].上海交通大学学报:医学版, 2008, 28(8): 944-947.

[38]

Engert A, Kobe C, Markova J, et al. Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: Final report of the GHSG HL15 trial[J]. Blood(ASH Annual Meeting Abstracts), 2010, 116(21): 336.

[39]

Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma[J]. Blood, 2008, 112(10): 3989-3994. doi: 10.1182/blood-2008-06-155820

[40]

Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin′s lymphoma: the importance of involved-field radiotherapy[J]. Ann Oncol, 2009, 20(11): 1848-1853. doi: 10.1093/annonc/mdp071

[41]

Schaefer NG, Taverna C, Strobel K, et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?[J]. Radiology, 2007, 244(1): 257-262. doi: 10.1148/radiol.2441060810

[42]

Zanoni L, Cerci JJ, Fanti S. Use of PET/CT to evaluate response to therapy in lymphoma[J]. Q J Nucl Med Mol imaging, 2011, 55(6): 633-647.

[43]

Sonoda LI, Sanghera B, Wong WL. Investigation of dose minimisation protocol for ¹⁸F-FDG PET-CT in the management of lymphoma postchemotherapy followup[J/OL]. Sci World J, 2012, 2012: 208135[2014-05-20]. http://www.hindawi.com/journals/tswj/2012/208135.

[44]

Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin′s lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?[J]. Ann Oncol, 2010, 21(5): 1053-1057. doi: 10.1093/annonc/mdp519

[45]

Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis[J]. Cancer, 2010, 116(16): 3835-3842. doi: 10.1002/cncr.25240

[46]

Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma[J]. Haematologica, 2007, 92(6): 771-777. doi: 10.3324/haematol.10798

[47]

El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs[J]. Haematologica, 2012, 97(6): 931-936. doi: 10.3324/haematol.2011.056010

[48]

Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin′s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients[J]. AJR Am J Roentgenol, 2008, 191(1): 32-37. doi: 10.2214/AJR.07.3112

[49]

Cole PD, McCarten KM, Drachtman RA, et al. Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine for Refractory Hodgkin Disease: A Children′s Oncology Group Report[J]. Pediatr Hematol Oncol, 2010, 27(8): 650-657. doi: 10.3109/08880018.2010.504250

[50]

Dodero A, Crocchiolo R, Patriarca F, et al. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation[J]. Cancer, 2010, 116(21): 5001-5011. doi: 10.1002/cncr.25357

[51]

Ghai S, Pattison J, Ghai S, et al. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation[J]. Radiographics, 2007, 27(5): 1371-1388. doi: 10.1148/rg.275065151

[52]

Huang MQ, Nelson DS, Pickup S, et al. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS[J]. Acad Radiol, 2007, 14(12): 1531-1539. doi: 10.1016/j.acra.2007.07.012

[53]

Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of ¹⁸F-FLT and ¹⁸F-FDG uptake on PET with Ki-67 immunohistoehemistry in non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2007, 34(10): 1610-1616. doi: 10.1007/s00259-007-0449-7

[54]

Troost EG, Vogel WV, Merkx MA, et al. ¹⁸F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients[J]. J Nucl Med, 2007, 48(5): 726-735. doi: 10.2967/jnumed.106.037473

[55]

Lawrence J, Vanderhoek M, Barbee D, et al. Use of 3'-deoxy-3'[¹⁸F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin′s lymphoma[J]. Vet Radiol U1trasound, 2009, 50(6): 660-668. doi: 10.1111/j.1740-8261.2009.01612.x

[56]

Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma[J]. Cancer Res, 2006, 66(22): 11055-11061. doi: 10.1158/0008-5472.CAN-06-1955

[57]

王瑞民, 朱海燕, 李菲, 等. ¹⁸F-FLT PET/CT在弥漫大B细胞淋巴瘤诊断及分期中的价值[J].中国实验血液学杂志, 2012, 20(3): 603-607.

[58]

Herrmann K, Buck AK, Schuster T, et al. Predictive Value of initial ¹⁸F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment[J]. J Nucl Med, 2011, 52(5): 690-696. doi: 10.2967/jnumed.110.084566